Frontline ATRA/Arsenic Trioxide Improves Survival in APL

The advantage of treating low- or intermediate-risk APL with ATRA plus arsenic trioxide appears to increase over time, according to results of the APL0406 trial.

Source: CancerNetwork - July 19, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news